565 related articles for article (PubMed ID: 9741514)
1. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
Dries DL; Exner DV; Gersh BJ; Domanski MJ; Waclawiw MA; Stevenson LW
J Am Coll Cardiol; 1998 Sep; 32(3):695-703. PubMed ID: 9741514
[TBL] [Abstract][Full Text] [Related]
2. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.
Exner DV; Dries DL; Waclawiw MA; Shelton B; Domanski MJ
J Am Coll Cardiol; 1999 Mar; 33(4):916-23. PubMed ID: 10091816
[TBL] [Abstract][Full Text] [Related]
3. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.
Dries DL; Exner DV; Domanski MJ; Greenberg B; Stevenson LW
J Am Coll Cardiol; 2000 Mar; 35(3):681-9. PubMed ID: 10716471
[TBL] [Abstract][Full Text] [Related]
4. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
[TBL] [Abstract][Full Text] [Related]
6. Racial differences in the outcome of left ventricular dysfunction.
Dries DL; Exner DV; Gersh BJ; Cooper HA; Carson PE; Domanski MJ
N Engl J Med; 1999 Feb; 340(8):609-16. PubMed ID: 10029645
[TBL] [Abstract][Full Text] [Related]
7. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
Jong P; Yusuf S; Rousseau MF; Ahn SA; Bangdiwala SI
Lancet; 2003 May; 361(9372):1843-8. PubMed ID: 12788569
[TBL] [Abstract][Full Text] [Related]
8. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Swedberg K; Olsson LG; Charlesworth A; Cleland J; Hanrath P; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson P
Eur Heart J; 2005 Jul; 26(13):1303-8. PubMed ID: 15767288
[TBL] [Abstract][Full Text] [Related]
10. The effect of gender on outcome in digitalis-treated heart failure patients.
Domanski M; Fleg J; Bristow M; Knox S
J Card Fail; 2005 Mar; 11(2):83-6. PubMed ID: 15732025
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
[TBL] [Abstract][Full Text] [Related]
12. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
[TBL] [Abstract][Full Text] [Related]
13. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators.
Konstam V; Salem D; Pouleur H; Kostis J; Gorkin L; Shumaker S; Mottard I; Woods P; Konstam MA; Yusuf S
Am J Cardiol; 1996 Oct; 78(8):890-5. PubMed ID: 8888661
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
[TBL] [Abstract][Full Text] [Related]
15. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.
Alsheikh-Ali AA; Wang PJ; Rand W; Konstam MA; Homoud MK; Link MS; Estes NA; Salem DN; Al-Ahmad AM
Am Heart J; 2004 Jun; 147(6):1061-5. PubMed ID: 15199356
[TBL] [Abstract][Full Text] [Related]
16. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
[TBL] [Abstract][Full Text] [Related]
17. [2 year follow-up of 321 patients with an implantable cardioverter/defibrillator: comparison of patients with and without atrial fibrillation].
Ryan S; Siemon G; Drögemüller A; Rameken M; Vater M; Senges J; Seidl K
Z Kardiol; 2001 Dec; 90(12):906-15. PubMed ID: 11826832
[TBL] [Abstract][Full Text] [Related]
18. Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE).
Al-Zakwani I; Sulaiman K; Al-Lawati JA; Alsheikh-Ali AA; Panduranga P; Al-Habib KF; Al Suwaidi J; Al-Mahmeed W; Al-Faleh H; Elasfar A; Al-Motarreb A; Ridha M; Bulbanat B; Al-Jarallah M; Bazargani N; Asaad N; Amin H
Curr Vasc Pharmacol; 2018; 16(6):596-602. PubMed ID: 28820057
[TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
Flaker GC; Blackshear JL; McBride R; Kronmal RA; Halperin JL; Hart RG
J Am Coll Cardiol; 1992 Sep; 20(3):527-32. PubMed ID: 1512329
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.
Al-Khadra AS; Salem DN; Rand WM; Udelson JE; Smith JJ; Konstam MA
J Am Coll Cardiol; 1998 Feb; 31(2):419-25. PubMed ID: 9462588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
